Weekly channel feed

BIO in tu­mult as CEO abrupt­ly ex­its; Some good PhI­II news; Da­ta is­sues still plague No­var­tis' gene ther­a­py; Hot tar­gets for M&A?; and more

11 months ago

Taste of M&A Mon­day; A spe­cial kind of lab; Biotech founder wins No­bel; Bio­Marin lay­offs; and more

11 months ago

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

12 months ago

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Last year

On heels of Lumakras da­ta drop, new KRAS idea emerges; Bris­tol My­ers, Ab­b­Vie, Ru­bius head­line busy week of re­struc­tur­ing; and more

Last year

Bris­tol My­ers Squibb scores TYK2 OK; ARCH backs mR­NA plat­form play; Il­lu­mi­na’s $8B co­nun­drum; Siz­ing up Al­ny­lam's win; and more

Last year

Lat­est news on FDA’s sec­ond look at Amy­lyx; Un­pack­ing Parkin­son’s R&D; Fiona Mar­shall takes over NI­BR from Jay Brad­ner; and more

Last year

Mod­er­na goes on the patent of­fen­sive; Pablo Legor­re­ta dou­bles down; Is a biotech re­cov­ery on the way?; and more

Last year

Roche's big Chi­na play; Mer­ck bets on mR­NA, again; Blue­bird's gene ther­a­py takes off; Bet­ter PhI­II? At a frac­tion of the cost?; and more

Last year

His­toric drug pric­ing re­forms pass; Pfiz­er ac­quires GBT; The long search for non-opi­oid pain drugs; and more

Last year

A $5B Pfiz­er buy­out? Am­gen, Gilead head­line M&A Thurs­day; Al­ny­lam's AT­TR sweep; An­drew Lo's rare dis­ease quest; and more

Last year

Big Phar­ma's in­creas­ing M&A en­thu­si­asm; Manchin, Schumer reach deal on drug pric­ing; Earn­ings re­caps; and more

Last year

Churn in FDA’s in­spec­tion unit; Roche’s chang­ing of the guard; Il­lu­mi­na on de­fense; NASH be­liev­er finds new chal­lenge; and more

Last year

No­var­tis' big PD-1 bet turns sour; $350M res­ur­rec­tion sto­ry; Con­tra­cep­tive for men heads to clin­ic; and more

Last year

Bis­pe­cif­ic M&A reach­es As­traZeneca; Count­down for Mer­ck­'s big bid; Biotech buy­out in sav­age times; and more

Last year

Phar­ma re­acts to post-Roe; Drug­mak­ers beef up cy­ber de­fense; Boehringer, Roche qui­et­ly axe drugs; and more

Last year

15 LGBTQ lead­ers in bio­phar­ma; Paul Stof­fels’ Gala­pa­gos re­vamp; As­traZeneca catch­es up in AT­TR; and more

Last year

Lat­est news on thumbs down for Nu­plazid; Amy­lyx’s first ALS ap­proval; Buy­out buzz for trou­bled biotechs; Cannes Li­ons pre­view; and more

Last year

Pre­view­ing bio­phar­ma trends ahead of #BIO22; Look­ing back at #AS­CO22; Smooth flight for blue­bird?; and more

Last year

Lat­est news out of #AS­CO22; GSK, Bris­tol My­ers get M&A go­ing in vac­cines, on­col­o­gy; Roche's pact spot­lights new can­cer tar­get; and more

Last year

Bio­mark­er 'roadmap­s' and the fu­ture of can­cer R&D; Cur­tain rais­es on #AS­CO22; Pfiz­er, No­var­tis tack­le drug ac­cess; and more

Last year

Amid mon­key­pox fears, biotechs spring to ac­tion; Mod­er­na’s CFO trou­ble; Cuts, cuts every­where; Craft­ing the right pro­teins; and more

Last year

Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and more

Last year

Bio­gen's shake­up from the top; How to build a biotech to­day; David Saba­ti­ni backs out of NYU; and more

Last year
First page Previous page 123456 Next page Last page
A service from the Financial Times